{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:20:29Z","timestamp":1770355229677,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["30125"],"award-info":[{"award-number":["30125"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007465","name":"Universitetet i Troms&amp;#x00F8;","doi-asserted-by":"publisher","award":["30012"],"award-info":[{"award-number":["30012"]}],"id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of steroid hormones in carcinogenesis of the prostate is to some extent unraveled thorough the effect of androgen deprivation therapy on prostate cancer (PCa) progression. Other members of the steroid hormone family, such as progesterone, are also implicated in PCa, but progesterone\u2019s role remains undefined. This study aimed to examine the distribution of progesterone receptor isoforms (PGRA, PGRB) in PCa tissue and their association with clinical endpoints. This was conducted retrospectively by collecting radical prostatectomy specimens from 535 patients. Tissue was analyzed using tissue microarray, where representative tumor areas were carefully selected. Protein expression was evaluated through immunohistochemistry, in stromal and epithelial tissue. Associations between receptor expression and clinical data were considered using statistical survival analyses. Herein, we discovered a solely stromal PGRA- and a stromal and epithelial PGRB expression. Further, a high PGRB expression in tumor tissue was associated with an unfavorable prognosis in both univariate and multivariate analyses: Biochemical failure (HR: 2.0, 95% CI: 1.45\u20132.76, p\u2009&lt;\u20090.001) and clinical failure (HR: 2.5, 95% CI: 1.29\u20134.85, p\u2009=\u20090.006). These findings are in agreement with our previous investigation on pan-PGR, indicating that the observed negative effect of PGR is represented by PGRB.<\/jats:p>","DOI":"10.1038\/s41598-018-29520-5","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T10:46:15Z","timestamp":1532342775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression"],"prefix":"10.1038","volume":"8","author":[{"given":"Thea","family":"Grindstad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin","family":"Richardsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigve","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaja","family":"Skjefstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Rakaee khanehkenari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Donnem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Ness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2237-4401","authenticated-orcid":false,"given":"Yngve","family":"Nordby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M.","family":"Bremnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Al-Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lill-Tove","family":"Busund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"29520_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"Collaboration, G. B. of D. C","year":"2017","unstructured":"Collaboration, G. B. of D. C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3, 524\u2013548 (2017).","journal-title":"JAMA Oncol."},{"key":"29520_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138\u201348 (2013).","journal-title":"N. Engl. J. Med."},{"key":"29520_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424\u201333 (2014).","journal-title":"N. Engl. J. Med."},{"key":"29520_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/bjc.2017.171","volume":"117","author":"K Cyll","year":"2017","unstructured":"Cyll, K. et al. Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br. J. Cancer 117, 367\u2013375 (2017).","journal-title":"Br. J. Cancer"},{"key":"29520_CR5","unstructured":"Gardner, D. G. et al. Greenspan\u2019s Basic and Clinical Endocrinology. McGraw Hill (2011)."},{"key":"29520_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins, C., Stevens, R. E. & Hodges, C. V. Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209\u2013223 (1941).","journal-title":"Arch. Surg."},{"key":"29520_CR7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0021-9258(19)40024-0","volume":"265","author":"PF Blackmore","year":"1990","unstructured":"Blackmore, P. F., Beebe, S. J., Danforth, D. R. & Alexander, N. Progesterone and 17 alpha-hydroxyprogesterone. Novel stimulators of calcium influx in human sperm. J. Biol. Chem. 265, 1376\u201380 (1990).","journal-title":"J. Biol. Chem."},{"key":"29520_CR8","first-page":"1347","volume":"8","author":"CA Sartorius","year":"1994","unstructured":"Sartorius, C. A. et al. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol. Endocrinol. 8, 1347\u20131360 (1994).","journal-title":"Mol. Endocrinol."},{"key":"29520_CR9","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1074\/jbc.M110090200","volume":"277","author":"JK Richer","year":"2002","unstructured":"Richer, J. K. et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem. 277, 5209\u201318 (2002).","journal-title":"J. Biol. Chem."},{"key":"29520_CR10","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1210\/me.2006-0105","volume":"20","author":"L Tung","year":"2006","unstructured":"Tung, L. et al. Progesterone Receptors (PR)-B and -A Regulate Transcription by Different Mechanisms: AF-3 Exerts Regulatory Control over Coactivator Binding to PR-B. Mol. Endocrinol. 20, 2656\u20132670 (2006).","journal-title":"Mol. Endocrinol."},{"key":"29520_CR11","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(17)38062-6","volume":"253","author":"KB Horwitz","year":"1978","unstructured":"Horwitz, K. B. & McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J. Biol. Chem. 253, 2223\u20132228 (1978).","journal-title":"J. Biol. Chem."},{"key":"29520_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1014820500738","volume":"72","author":"PA Mote","year":"2002","unstructured":"Mote, P. A., Bartow, S., Tran, N. & Clarke, C. L. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat. 72, 163\u2013172 (2002).","journal-title":"Breast Cancer Res. Treat."},{"key":"29520_CR13","unstructured":"H, S. et al. Progesterone receptor agonists, antagonists and isoforms differentially reprogram estrogen signaling in breast cancer. Endocr. Rev. 37 (2016)."},{"key":"29520_CR14","first-page":"4576","volume":"61","author":"RL Arnett-Mansfield","year":"2001","unstructured":"Arnett-Mansfield, R. L. et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 61, 4576\u20134582 (2001).","journal-title":"Cancer Res."},{"key":"29520_CR15","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1210\/jc.2012-4000","volume":"98","author":"Y Yu","year":"2013","unstructured":"Yu, Y. et al. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J. Clin. Endocrinol. Metab. 98, 2887\u201396 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"29520_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pros.1108","volume":"48","author":"H Bonkhoff","year":"2001","unstructured":"Bonkhoff, H., Fixemer, T., Hunsicker, I. & Remberger, K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate 48, 285\u201391 (2001).","journal-title":"Prostate"},{"key":"29520_CR17","first-page":"1919","volume":"61","author":"A Latil","year":"2001","unstructured":"Latil, A. et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61, 1919\u20131926 (2001).","journal-title":"Cancer Res."},{"key":"29520_CR18","doi-asserted-by":"crossref","unstructured":"Grindstad, T. et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One 10 (2015).","DOI":"10.1371\/journal.pone.0116691"},{"key":"29520_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1677\/joe.1.06348","volume":"189","author":"CM Luetjens","year":"2006","unstructured":"Luetjens, C. M. et al. Tissue expression of the nuclear progesterone receptor in male non-human primates and men. J. Endocrinol. 189, 529\u2013539 (2006).","journal-title":"J. Endocrinol."},{"key":"29520_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.17305\/bjbms.2016.1209","volume":"16","author":"L Song","year":"2016","unstructured":"Song, L. et al. Diff erential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia. Bosn. J. basic Med. Sci. \/ Udruz\u030cenje basic\u030cnih Med. Znan.=Assoc. Basic Med. Sci. 16, 201\u20138 (2016).","journal-title":"Bosn. J. basic Med. Sci. \/ Udruz\u030cenje basic\u030cnih Med. Znan.=Assoc. Basic Med. Sci."},{"key":"29520_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.steroids.2015.01.020","volume":"98","author":"K Skjefstad","year":"2015","unstructured":"Skjefstad, K. et al. The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival. Steroids 98, 29\u201336 (2015).","journal-title":"Steroids"},{"key":"29520_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.arcmed.2016.10.002","volume":"47","author":"L Germ\u00e1n-Castel\u00e1n","year":"2016","unstructured":"Germ\u00e1n-Castel\u00e1n, L., Manjarrez-Marmolejo, J., Gonz\u00e1lez-Arenas, A. & Camacho-Arroyo, I. Intracellular Progesterone Receptor Mediates the Increase in Glioblastoma Growth Induced by Progesterone in the Rat Brain. Arch. Med. Res. 47, 419\u2013426 (2016).","journal-title":"Arch. Med. Res."},{"key":"29520_CR23","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol. 17, 1471\u20131474 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"29520_CR24","doi-asserted-by":"crossref","unstructured":"Sobin, L., Gospodarowicz, M., W. C. TNM Classification of Malignant Tumours, 7th Edition. Wiley 243\u2013246 (2009).","DOI":"10.1002\/9780471420194.tnmc26"},{"key":"29520_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur. Urol. 69, 428\u2013435 (2016).","journal-title":"Eur. Urol."},{"key":"29520_CR26","doi-asserted-by":"crossref","unstructured":"Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am. J. Surg. Pathol. 40 (2016).","DOI":"10.1097\/PAS.0000000000000530"},{"key":"29520_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-14-49","volume":"14","author":"S Andersen","year":"2014","unstructured":"Andersen, S. et al. Disease-specific outcomes of Radical Prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol. 14, 49 (2014).","journal-title":"BMC Urol."},{"key":"29520_CR28","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1200\/JCO.2002.08.159","volume":"20","author":"RM Bremnes","year":"2002","unstructured":"Bremnes, R. M. et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 20, 2417\u20132428 (2002).","journal-title":"J. Clin. Oncol."},{"key":"29520_CR29","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"MEH Hammond","year":"2010","unstructured":"Hammond, M. E. H. et al. American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J. Clin. Oncol. 28, 2784\u20132795 (2010).","journal-title":"J. Clin. Oncol."},{"key":"29520_CR30","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","volume":"24","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson, A. J. et al. Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition. J. Clin. Oncol. 24, 3973\u20133978 (2006).","journal-title":"J. Clin. Oncol."},{"key":"29520_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane, L. M. et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100, 229\u2013235 (2006).","journal-title":"Breast Cancer Res. Treat."},{"key":"29520_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jsbmb.2016.04.008","volume":"166","author":"R Chen","year":"2017","unstructured":"Chen, R., Yu, Y. & Dong, X. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer. J. Steroid Biochem. Mol. Biol. 166, 91\u201396 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"29520_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/pros.22988","volume":"75","author":"Y Yu","year":"2015","unstructured":"Yu, Y. et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate 75, 1043\u20131050 (2015).","journal-title":"Prostate"},{"key":"29520_CR34","doi-asserted-by":"publisher","first-page":"e92714","DOI":"10.1371\/journal.pone.0092714","volume":"9","author":"Y Yu","year":"2014","unstructured":"Yu, Y. et al. Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility. PLoS One 9, e92714 (2014).","journal-title":"PLoS One"},{"key":"29520_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/jcp.54.8.624","volume":"54","author":"PA Mote","year":"2001","unstructured":"Mote, P. A., Johnston, J. F., Manninen, T., Tuohimaa, P. & Clarke, C. L. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J. Clin. Pathol. 54, 624\u2013630 (2001).","journal-title":"J. Clin. Pathol."},{"key":"29520_CR36","doi-asserted-by":"publisher","unstructured":"Scarpin, K. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl. Recept. Signal, https:\/\/doi.org\/10.1621\/nrs.07009 (2009).","DOI":"10.1621\/nrs.07009"},{"key":"29520_CR37","first-page":"2963","volume":"84","author":"PA Mote","year":"1999","unstructured":"Mote, P. A., Balleine, R. L., McGowan, E. M. & Clarke, C. L. Colocalization of progesterone receptors a and b by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 84, 2963\u20132971 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"29520_CR38","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VKK Arora","year":"2013","unstructured":"Arora, V. K. K. et al. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell 155, 1309\u20131322 (2013).","journal-title":"Cell"},{"key":"29520_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","volume":"5","author":"M Isikbay","year":"2014","unstructured":"Isikbay, M. et al. Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer. Horm. Cancer 5, 72\u201389 (2014).","journal-title":"Horm. Cancer"},{"key":"29520_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed, H. et al. Progesterone receptor modulates ER\u03b1 action in breast cancer. Nature 523, 313\u2013317 (2015).","journal-title":"Nature"},{"key":"29520_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/onc.2013.579","volume":"34","author":"AR Daniel","year":"2015","unstructured":"Daniel, A. R. et al. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34, 506\u2013515 (2015).","journal-title":"Oncogene"},{"key":"29520_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0022-4731(89)90098-8","volume":"34","author":"AO Brinkmann","year":"1989","unstructured":"Brinkmann, A. O. et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem. 34, 307\u2013310 (1989).","journal-title":"J. Steroid Biochem."},{"key":"29520_CR43","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1158\/0008-5472.CAN-04-4076","volume":"65","author":"H-J Zhou","year":"2005","unstructured":"Zhou, H.-J. et al. SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival. Cancer Res. 65, 7976\u20137983 (2005).","journal-title":"Cancer Res."},{"key":"29520_CR44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1172\/JCI76029","volume":"125","author":"S Dasgupta","year":"2015","unstructured":"Dasgupta, S. et al. Coactivator SRC-2\u2032 dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J. Clin. Invest. 125, 1174\u20131188 (2015).","journal-title":"J. Clin. Invest."},{"key":"29520_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1210\/me.2003-0189","volume":"18","author":"L-N Song","year":"2004","unstructured":"Song, L.-N., Coghlan, M. & Gelmann, E. P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18, 70\u201385 (2004).","journal-title":"Mol. Endocrinol."},{"key":"29520_CR46","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/j.1464-410X.2008.07509.x","volume":"101","author":"ME Taplin","year":"2008","unstructured":"Taplin, M. E. et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 101, 1084\u20131089 (2008).","journal-title":"BJU Int."},{"key":"29520_CR47","doi-asserted-by":"crossref","first-page":"TPS5097","DOI":"10.1200\/jco.2014.32.15_suppl.tps5097","volume":"32","author":"J Mateo","year":"2014","unstructured":"Mateo, J. et al. A phase 1\u20132 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 32, TPS5097\u2013TPS5097 (2014).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29520-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:36:06Z","timestamp":1720449366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["29520"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-29520-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11358"}}